Kwandong, Salvat ink agreement over OAB medicine
Published: 2010-11-25 06:57:00
Updated: 2010-11-25 06:57:00
Kwangdong Pharmaceutical said on November 16 that it has signed a licensing agreement with Spain based Laboratorios SALVAT, S.A. (Salvat), granting the former the rights to develop, register and market Tarafenacin in Korea for overactive bladder syndrome (OAB).
Under the terms of the agreement...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
